Mendilex pills 2mg, 50pcs

Composition

>of 1 tab. contains: Active ingredients:  biperidene hydrochloride 2 mg. Auxiliary substances: magnesium stearate 2 mg, lactose monohydrate 65 mg, microcrystalline cellulose 131 mg

Pharmacological action

Mendilex (biperiden) is a central-acting cholinoblocking drug with a moderate peripheral effect. As a result of selective blockade of cholinergic receptors, biperiden leads to a weakening of the signs of Parkinsonism (akathisia, muscle rigidity, akinesia, dyskinetic tremor, oculogyric crisis).

Indications

Parkinsonism syndrome (as part of combination therapy), including the initial stages of Parkinson’s disease (monotherapy).

Extrapyramidal disorders (tremor, muscle rigidity, torsion dystonia and local forms of dystonia, including paroxysmal dyskinesia, chorea hyperkinesis, various forms of tics, myoclonia and hyperkinesis, dystonia of the muscles of the limbs, trunk, neck, face, akinesia, akathisia) caused by drugs (in particular neuroleptics).

Use during pregnancy and lactation

use during pregnancy is possible if the benefit to the mother exceeds the possible risk to the fetus. When prescribed during lactation, it is necessary to stop breastfeeding. The drug is excreted in breast milk and the child may develop anticholinergic effects.

Recommendations for use

Inside. In Parkinson’s disease and Parkinsonism, the initial dose is 2 mg per day, divided into two doses. The dose is gradually increased until the optimal daily dose is reached, which for most patients is 3-12 mg (divided into 3-4 doses). The maximum daily dose is 16 mg. Usually, adults with extrapyramidal disorders caused by drugs (in particular, neuroleptics) are prescribed 2 mg,1-3 times a day. It is necessary to avoid sudden discontinuation of treatment due to the high probability of withdrawal symptoms.

Contraindications

Hypersensitivity, myasthenia gravis, angle-closure glaucoma, intestinal obstruction, urinary tract obstruction, paralytic intestinal obstruction or intestinal atony, gastroesophageal reflux, ulcerative colitis, toxic megacolon, acute bleeding.

With caution.

Elderly patients and patients suffering from prostatic hypertrophy, tachyarrhythmia, congestive heart failure, coronary heart disease, arterial hypertension, ileostomy/colostomy, epilepsy.

Children under 18 years of age (efficacy and safety of the drug in children has not been established).

Side effects

Basically, side effects develop as a result of the anticholinergic action of the drug. Most often, dry mouth, mydriasis, paresis of accommodation are observed, which are dose-dependent side effects. Rarely constipation, dyspepsia, fatigue, weakness, dizziness, drowsiness, anxiety, confusion, memory impairment, hallucinations, euphoria, disorientation in time and space, motor agitation, catalepsy, urinary retention, tachycardia, low blood pressure, drug dependence, allergic reactions (skin rash).

Interaction

Increases the effect of M-holinoblokatorov, antihistamines, antiparkinsonian and antiepileptic drugs, weakens the effect of metoclopramide.

Incompatible with ethanol.

Levodopa increases the M-cholinoblocking effect, while quinidine increases the risk of dyskinesia.

Overdose

Symptoms of overdose are similar to those of atropine poisoning: mydriasis, dry skin, flushing of the face, dry mouth and upper respiratory tract, increased body temperature, tachycardia, cardiac arrhythmias, weakening of intestinal motility, urinary retention, delirium, disorientation, anxiosis, hallucinations, confusion, ataxia, aggressiveness and convulsions.

With severe poisoning, stupor, comatose state, respiratory and cardiac arrest, and death are possible.

Assistance: gastric lavage, symptomatic therapy. It is recommended to prescribe physostigmine as a specific antagonist at a dose of 1 mg/m or by slow intravenous infusion.

This dose can be repeated every 20 minutes, but the total amount should not exceed 4 mg per day. Since physostigmine is rapidly metabolized, an additional infusion of physostigmine is sometimes necessary every 1-2 hours. For children and elderly patients, half the standard dose is recommended.

The patient should be monitored by a doctor for at least 8-12 hours after the last onset of symptoms.

Special instructions

The use of biperidene can cause neuromuscular blockage, followed by muscle weakness and paralysis.

Do not drink alcohol during treatment with biperiden.

In susceptible patients, confusion, euphoria, and motor arousal are observed when prescribing an anticholinergic drug at the recommended therapeutic doses.

Influence on the ability to drive vehicles and mechanisms

The drug has a strong effect on psychomotor reactions, which is why patients taking the drug should refrain from engaging in potentially dangerous activities that require rapid mental and motor reactions.

Storage conditions

List A. Store the product in a place protected from light at a temperature of 15-25°C. Keep out of reach of children.

Shelf

life is 5 years. Do not use after the expiration date.

Active ingredient

Biperiden

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For pregnant women as prescribed by a doctor, For adults as prescribed by a doctor

Indications

Parkinson ‘s Disease